List of Secuado drug patents

Secuado is owned by Hisamitsu.

Secuado contains Asenapine.

Secuado has a total of 5 drug patents out of which 0 drug patents have expired.

Secuado was authorised for market use on 11 October, 2019.

Secuado is available in system;transdermal dosage forms.

Secuado can be used as method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch.

The generics of Secuado are possible to be released after 25 July, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583121 HISAMITSU Patch
Jul, 2033

(10 years from now)

US10814002 HISAMITSU Patch and method for producing the same
Jul, 2033

(10 years from now)

US9687474 HISAMITSU Patch
Jul, 2033

(10 years from now)

US10022445 HISAMITSU Patch
Jul, 2033

(10 years from now)

US11123305 HISAMITSU Patch
Jul, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 11, 2022

Drugs and Companies using ASENAPINE ingredient

Market Authorisation Date: 11 October, 2019

Treatment: Method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

SECUADO family patents

15

United States

10

Japan

3

Spain

3

Korea, Republic of

3

Taiwan, Province of China

3

China

3

European Union

2

Portugal

2

Poland

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in